SIGA TECHNOLOGIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.61 USD | -3.67% |
|
+2.01% | +35.89% |
| 07/05 | Earnings Flash (SIGA) SIGA TECHNOLOGIES Reports Q1 Revenue $25.4M | MT |
| 07/05 | Transcript : SIGA Technologies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 178M 14.78B | Sales 2025 * | 162M 13.46B | Capitalization | 541M 45.06B |
|---|---|---|---|---|---|
| Net income 2024 * | 83M 6.91B | Net income 2025 * | 75M 6.24B | EV / Sales 2024 * | 2.11 x |
| Net cash position 2024 * | 166M 13.83B | Net cash position 2025 * | 190M 15.79B | EV / Sales 2025 * | 2.18 x |
| P/E ratio 2024 * |
6.45
x | P/E ratio 2025 * |
7.11
x | Employees | 45 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on SIGA Technologies, Inc.
More press releases
More news
| 1 day | -3.67% | ||
| 1 week | +2.01% | ||
| Current month | -13.33% | ||
| 1 month | -8.75% | ||
| 3 months | +47.77% | ||
| 6 months | +46.07% | ||
| Current year | +35.89% |
1 week
7.29
8.11
1 month
7.1310.83
Current year
4.2610.83
1 year
4.2210.83
3 years
4.2226.99
5 years
3.9626.99
10 years
0.2026.99
| Managers | Title | Age | Since |
|---|---|---|---|
Diem Nguyen
CEO | Chief Executive Officer | 52 | 27/01 |
Daniel Luckshire
DFI | Director of Finance/CFO | 53 | 10/11/10 |
Tove C. Bolken
COO | Chief Operating Officer | - | 01/98/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Marshall
BRD | Director/Board Member | 71 | 11/09/11 |
Jaymie Durnan
BRD | Director/Board Member | 70 | 16/20/16 |
Harold Ford
BRD | Director/Board Member | 53 | 10/22/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.48% | 28 M€ | -0.48% | ||
| 0.16% | 25 M€ | -1.43% | - | |
| 0.01% | 430 M€ | -.--% | ||
| 0.01% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 7.61 | -3.67% | 992,566 |
| 16/24/16 | 7.9 | +1.28% | 599,666 |
| 15/24/15 | 7.8 | -0.64% | 840,495 |
| 14/24/14 | 7.85 | +5.37% | 1,130,960 |
| 13/24/13 | 7.45 | -0.13% | 981,314 |
Delayed Quote Nasdaq, May 18, 2024 at 01:30 am IST
More quotes
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
Sector
Pharmaceuticals
Calendar
11/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.89% | 541M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.74% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- SIGA Stock
